Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research report sent to investors on Monday,Benzinga reports. The firm currently has a $10.00 price target on the stock.

Several other brokerages also recently weighed in on AQST. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price for the company. Lake Street Capital decreased their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $10.57.

Aquestive Therapeutics Trading Down 4.2 %

AQST opened at $2.54 on Monday. Aquestive Therapeutics has a 12 month low of $2.24 and a 12 month high of $6.23. The stock has a fifty day moving average price of $3.07 and a 200-day moving average price of $4.09. The firm has a market cap of $251.13 million, a price-to-earnings ratio of -5.64 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. On average, equities research analysts forecast that Aquestive Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds have recently made changes to their positions in the company. Chartwell Investment Partners LLC purchased a new stake in Aquestive Therapeutics during the 3rd quarter valued at about $535,000. GSA Capital Partners LLP lifted its holdings in shares of Aquestive Therapeutics by 525.5% during the third quarter. GSA Capital Partners LLP now owns 137,151 shares of the company’s stock worth $683,000 after purchasing an additional 115,223 shares during the period. Intech Investment Management LLC purchased a new stake in Aquestive Therapeutics in the third quarter valued at approximately $90,000. Charles Schwab Investment Management Inc. boosted its position in Aquestive Therapeutics by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock valued at $1,014,000 after buying an additional 9,268 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in Aquestive Therapeutics in the 3rd quarter worth approximately $135,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.